Gelonghui, on December 31, announced that C-MER MEDICAL (03309.HK) has released a statement. On December 31, 2024, the company's wholly-owned subsidiary C-MER MEDICAL Group entered into a Series A investment agreement with HEALTH CARE A, under which C-MER MEDICAL Group agreed to invest 1 million USD in HEALTH CARE A as part of its Series A fundraising round.
According to the terms of the Series A investment agreement and after the completion of the Series A round of HEALTH CARE A, it is expected that the group will Hold approximately 23% of the total issued shares of HEALTH CARE A (expanded after the issuance of new shares to Series A investors), together with its existing shares in HEALTH CARE A prior to the investment.
HEALTH CARE A is a clinical-stage biotechnology company headquartered in Hong Kong, with a range of oral anticancer projects aimed at replacing the currently popular intravenous chemotherapy drugs, making home-based chemotherapy possible.
